Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NYSE:QGEN

Qiagen Q3 2026 Earnings Date & Estimates

Qiagen logo
$50.42 +0.20 (+0.39%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$50.38 -0.04 (-0.08%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Qiagen is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Qiagen in Q3 2026

Qiagen is expected to post earnings of $0.6270 per share on revenue of $538.61 million. In the same quarter a year earlier Qiagen reported $0.6421 per share on revenue of $532.58 million. Qiagen last reported on August 5, 2026, posting $0.62 per share and beating the $0.5980 consensus estimate. Qiagen has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.6270
Expected Revenue
$538.61 million
Prior-Year EPS
$0.6421
Prior-Year Revenue
$532.58 million
Expected EPS Growth
-2.4%
Expected Revenue Growth
+1.1%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.62 (Beat by +$0.0220)
Last Quarter Revenue
$535.04 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Qiagen Q3 2026 Earnings FAQ

Qiagen (NYSE:QGEN) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Qiagen's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Qiagen to post earnings of $0.6270 per share for Q3 2026.

The consensus revenue estimate for Qiagen is $538.61 million for Q3 2026.

Qiagen Earnings Headlines

JPMorgan Chase & Co. Reaffirms Neutral Rating for Qiagen (NYSE:QGEN)
October 24 at 2:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151762
Qiagen (NYSE:QGEN) Stock Gets Price Target Increase from Robert W. Baird
October 24 at 2:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151764
$29.97 or $0 today
The 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightforward 3-step approach to trading same-day options, with entry, exit and max loss set before you ever place a trade. Plain English, no complicated math, done by market close. The price may return to 29.97 as soon as tomorrow.tc pixel
October 24 at 1:00 AM  |  Profits Run (Ad)
Qiagen (NYSE:QGEN) Stock Sees Unusually High Call Option Buying
October 24 at 1:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151621
Qiagen: Unanimous Acceptance Takeover Nears Close (Rating Downgrade)
October 23 at 8:33 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4956857-qiagen-unanimous-acceptance-takeover-nears-close-downgrade
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: QIAGEN N.V. (NYSE – QGEN), Varonis Systems, Inc. (Nasdaq – VRNS), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)
October 22 at 5:03 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386957/0/en/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-qiagen-n-v-nyse-qgen-varonis-systems-inc-nasdaq-vrns-ccc-intelligent-solutions-holdings-inc-nas.html
See More Qiagen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Qiagen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Qiagen and other key companies, straight to your email.

About Qiagen

Qiagen (NYSE:QGEN) (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables. QIAGEN also supplies molecular diagnostic tests used in areas such as infectious diseases, oncology and other clinical applications, including its QuantiFERON tuberculosis testing platform and QIAstat-Dx syndromic testing system.

Founded in 1984, QIAGEN serves academic, pharmaceutical, biotechnology, applied testing and healthcare customers. The company operates internationally, with products and services distributed across North America, Europe, Asia and other global markets, and maintains corporate operations in the Netherlands and the United States.

View Qiagen Profile
Earnings Tools